Abstract Details

Title PatientsLikeMe® Epilepsy Community: Factors Affecting Quality of Life

Topic Epilepsy

Presentation(s) P03 - (-)

Poster/Presentation
Number 122

Objective

Background BACKGROUND: The PatientsLikeMe Epilepsy Community is a free online platform developed in partnership with UCB (launched January 2010) that allows patients to record, monitor and share socio-demographic and clinical characteristics and complete standardized questionnaires measuring HRQoL and mood.

Design/Methods DESIGN/METHODS: Cross-sectional analyses of patient-reported outcomes. Multivariate logistic regressions were performed to identify variables associated with poor HRQoL (< Quartile 1 of Quality of Life in Epilepsy [QOLIE-31/P] total score).

Results RESULTS: By November 2011, 1121 patients (mean age 37.8 years; 72.2% female; mean epilepsy duration 17.8 years) who recorded a diagnosis of epilepsy and multiple seizures had completed the QOLIE-31/P. The median (Q1-Q3) QOLIE-31/P total score was 50.9 (37.3-65.4). Multivariate logistic regression indicated that poor HRQoL was more likely in patients reporting (Odds Ratio [95% confidence interval]): i) moderate/severe problems concentrating (2.96 [1.91-4.59], depression (2.53 [1.75-3.66]), memory problems (2.14 [1.39-3.30]), anxiety (1.62 [1.12-2.35]), fatigue (1.60 [1.05-2.44]); ii) moderate/severe side effects (2.11 [1.25-3.59]); iii) ?1 seizure during the 4 weeks preceding QOLIE-31/P completion (?1 tonic-clonic seizure 2.87 [1.65-4.99]; ?1 non-tonic-clonic seizure 1.61 [1.07-2.42]); iv) shorter epilepsy duration (?1 year 2.51 [1.41-4.45]; >1-10 years 1.71 [1.15-2.53]; both vs >10 years). Patients on newer antiepileptic drugs (AEDs) as monotherapy (0.32 [0.13-0.80]) or polytherapy (0.24 [0.10-0.61]) were less likely to report poor HRQoL than patients on polytherapy with older AEDs, as were patients not reporting AED treatment (0.26 [0.08-0.80]).

Conclusions CONCLUSIONS: The most predictive factors of poor HRQoL were moderate/severe problems concentrating, depression, memory problems, and side effects; occurrence of tonic-clonic seizures and epilepsy duration ?1 year. These results suggest that a holistic approach beyond seizure control should be considered when treating people with epilepsy.

Authors/Disclosures
Simon Borghs PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
Tracy Durgin, PharmD (Eisai)	No disclosure on file
Stephen D. Silberstein, MD, F�鶹��ýӳ��	Dr. Silberstein has received publishing royalties from a publication relating to health care.
	No disclosure on file
	No disclosure on file
	No disclosure on file
Paul Wicks, PhD	No disclosure on file

�鶹��ýӳ��

�鶹��ýӳ��